[Prognosis at six months for coronary patients: impact of antiplatelet agents and statins].
The aim of the PREVENIR III study was to assess, in secondary prevention, the risk after six months of subsequent coronary and cerebrovascular events. A prospective observational survey, including patients diagnosed with previous myocardial infarction, unstable angina or ischemic stroke, was carried out by French general practitioners and cardiologists. 9556 patients were selected by 3746 physicians representative of French physicians. The medical records of 6859 patients with previous unstable angina or myocardial infarction were analyzed. After a 6-month follow-up, 84 patients (1.2%) had been hospitalized for coronary or cerebrovascular event i.e. cumulative incidence 3.1 per 100 person-years (95% CI 2.4-3.8) and 67 patients died (1.0%) i.e. 2.5 per 100 person-years (95% CI 1.9-3.1). Patients treated with statins and antiplatelet agents were less likely to undergo subsequent vascular events (relative risk: 0.35; 95% CI 0.20-0.61) than patients not receiving statins or antiplatelet agents. All-cause mortality rate decreased dramatically (relative risk: 0.32; 95% CI 0.16-0.65) in patients treated with a combination of statins and antiplatelet agents when compared to patients treated with neither statins nor antiplatelet agents. This work enabled a better understanding of the prognosis at six months in a large sample of coronary patients. We observed the beneficial impact of the combination of statins and antiplatelet agents in secondary prevention.